The role of the sympathetic nervous system in obesity-related hypertension

Current Hypertension Reports

Volumn 11, Issue 3, 2009, Pages 206-211

  da Silva, Alexandre A ^a   Carmo, Jussara ^b   Dubinion, John ^b   Hall, John E ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADIPONECTIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; GHRELIN; INSULIN; LEPTIN; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN RECEPTOR AGONIST; SODIUM;

ABDOMINAL OBESITY; ADIPOCYTE; ADRENERGIC SYSTEM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; COMPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; ESSENTIAL HYPERTENSION; GASTROINTESTINAL SECRETION; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TUBULE ABSORPTION; NATRIURESIS; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PRESSORECEPTOR; PRESSORECEPTOR REFLEX; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC TONE; WEIGHT REDUCTION;

BLOOD PRESSURE; HUMANS; HYPERTENSION; OBESITY; PRESSORECEPTORS; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 65749095507     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0036-3     Document Type: Review

References (50)

1. Department of Health and Human Services-Centers for Disease Control and Prevention: Overweight and obesity trends among adults. 2008. Available at http://www.cdc.gov/nccdphp/dnpa/obesity/trend/index.htm. Accessed March 2009.
2. Wilson PWF, D'Agostino RB, Sullivan L, et al.: Overweight and obesity as determinants of cardiovascular risk-the Framingham experience. Arch Intern Med 2002, 162:1867-1872.
3. Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137.
4. Wannamethee SG, Shaper AG: Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999, 22:1266-1272.
5. Davy KP, Hall JE: ObTsity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 2004, 286:R803-R813.
6. Davy KP, Orr JS: Sympathetic nervous system behavior in human obesity. Neurosci Biobehav Rev 2009, 33:116-124.
7. Alexander J, Dustan HP, Sims EAH, et al.: Report of the Hypertension Task Force. US Department of Health, Education, and Welfare Publication No. 70-1631 (NIH), Washington, DC: US Government Printing Office; 1979:61-77.
8. Jones DW, Kim JS, Andrew ME, et al.: Body mass index and blood pressures in Korean men and women: The Korean National Blood Pressure Survey. J Hypertens 1994, 12:1433-1437.
9. Neter JE, Stam BE, Kok FL, et al.: Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension 2003, 42:878-884.
10. Guyton AC: The surprising kidney-fluid mechanism for pressure control'its infinite gain! Hypertension 1990, 16: 725-730.
11. Hall JE: The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
12. Hall JE, Brands, MW, Hildebrandt DA, et al.: Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res 2000, 33:605-618.
13. Wofford MR, Anderson DC, Brown CA, et al.: Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14:694-698.
14. Kassab S, Kato T, Wilkins C, et al.: Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25:893-897.
15. Straznicky NE, Eikelis N, Lambert EA, et al.: Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 2008, 10:440-447.
16. Grassi G, Dell'Oro R, Facchini A, et al.: Effect of central and peripheral obesity body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004, 22:2363-2369.
17. Schwartz MW, Woods SC, Porte D Jr, et al.: Central nervous system control of food intake. Nature 2000, 404:661-671.
18. Correia ML, Rahmouni K: Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006, 8:603-610.
19. Rahmouni K, Haynes WG, Morgan DA, et al.: Intracellular mechanisms involved in leptin regulation of sympathetic outflow. Hypertension 2003, 41:763-767.
20. Kimura K, Tsuda K, Baba A, et al.: Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 2000, 273:745-749.
21. Carlyle M, Jones OB, Kuo JJ, et al.: Chronic cardiovascular and renal actions of leptin-role of adrenergic activity. Hypertension 2002, 39:496-501.
22. Kuo JJ, Jones OB, Hall JE: Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001, 37:670-676.
23. Ozata M, Ozdemir IC, Licinio J: Human leptin deficiency caused by a missense mutation: Multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999, 10:3686-3695.
24. Haynes WG, Morgan DA, Djalali A, et al.: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999, 33:542-547.
25. da Silva AA, Kuo JJ, Hall JE: Role of hypothalamic melanocortin 3/ 4-receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension 2004, 43:1312-1317.
26. Tallam LS, Stec DE, Willis MA, et al.: Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension 2005, 46:326-332.
27. Tallam LS, da Silva AA, Hall JE: Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin. Hypertension 2006, 48:58-64.
28. Greenfield JR, Miller JW, Keogh JM, et al.: Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 2009, 360:44-52.
29. da Silva AA, do Carmo JM, Kanyicska B, et al.: Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats. Hypertension 2008, 51:884-890.
30. Wang ZV, Scherer PE: Adiponectin, cardiovascular function, and hypertension. Hypertension 2008, 51:8-14.
31. Pajvani UB, Hawkins M, Combs TP, et al.: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.
32. Ohashi K, Kihara S, Ouchi N, et al.: Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47:1108-1116.
33. Ouchi N, Ohishi M, Kihara S, et al.: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234.
34. Tanida M, Shen J, Horii Y, et al.: Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med 2007, 232:390-397.
35. Lin Y, Matsumura K, Fukuhara M, et al.: Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004, 43:977-982.
36. Matsumura K, Tsuchihashi T, Fujii K, et al.: Central ghrelin regulates sympathetic activity in conscious rabbits. Hypertension 2002, 40:694-699.
37. GilACampos M, Aguilera CM, Cañete R, et al.: Ghrelin: a hormone regulating food intake and energy homeostasis. Br J Nutr 2006, 96:201-226.
38. Xu X, Jhun BS, Ha CH, et al.: Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology 2008, 149:4183-4192.
39. Hall JE, Summers RL, Brands MW, et al.: Resistance to metabolic actions of insulin and its role in hypertension. Am J Hypertens 1994, 7:772-788.
40. Liu J, da Silva AA, Tallam LS, et al.: Chronic central nervous system hyperinsulinemia and regulation of arterial pressure and food intake. J Hypertens 2006, 24:1391-1395.
41. Hall JE, Jones DW, Kuo JJ, et al.: Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep 2003, 5:386-392.
42. Umemura S, Nyui N, Tamura K, et al.: Plasma angiotensinogen concentrations in obese patients. Am J Hypertens 1997, 10:629-633.
43. Reisin E, Weir MR, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: A multi-center placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997, 30:140-145.
44. de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41-47.
45. Carroll RG, Lohmeier TE, Brown AJ: Chronic angiotensin II infusion decreases renal norepinephrine overflow in the conscious dog. Hypertension 1984, 6:675-681.
46. Lohmeier TE, Dwyer TM, Hildebrandt DA, et al.: Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension 2005, 46:1194-1200.
47. Lohmeier TE, Lohmeier JR, Haque A, et al.: Baroreflexes prevent neurally induced sodium retention in angiotensin hypertension. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1437-R1448.
48. Lohmeier TE, Dwyer TM, Irwin ED, et al.: Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 2007, 49:1307-1314.
49. Biaggioni I: Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension 2008, 51:168-171.
50. Svetkey LP, Stevens VJ, Brantley PJ, et al.: Comparison of strategies for sustaining weight loss: The weight loss maintenance randomized controlled trial. JAMA 2008, 299:1139-1148.